Video
Dr. Stewart discusses study of neoadjuvant axitinib in renal cell carcinoma
Author(s):
Video Player is loading.
In this video, Grant Stewart, MD, discusses the background and findings of the study, “NAXIVA – a phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer with venous invasion: translational results.” Stewart is a professor of surgical oncology and honorary consultant urological surgeon at the University of Cambridge, England, United Kingdom.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
David Stanley, MD, on current trends in the management of kidney stones
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Post-RP incontinence: Low procedure rates examined
Roger Dmochowski, MD, on quality-of-life outcomes with the Revi System
Anne Schuckman, MD, highlights promising new developments in NMIBC
Amir Patel, MD, on onabotulinumtoxinA injection at the time of HoLEP
Data link incontinence severity to post-radical prostatectomy care
Margaret Knoedler, MD, on robot-assisted mini-PCNL with the MONARCH Platform
Khurshid Ghani, MBChB, MS, FRCS, on current barriers to stent omission
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Related Content
